Life After I-SPY Graduation: Neratinib Likely To Be Tested With Roche’s Perjeta
This article was originally published in The Pink Sheet Daily
Executive Summary
I-SPY 2 investigators are buoyed by “strong signal” for neratinib in high-risk subgroup in adaptive design study. Investors, however, are underwhelmed by results.
You may also be interested in...
R&D In Brief: Lilly’s Cyramza Cleared In Lung, SABCS & ASH Updates
Lilly adds significant new market for ramucirumab, while early data presented at San Antonio Breast Cancer Symposium and American Society of Hematology annual meeting pave the way for future filings.
Cancer Progress Requires Integrating Data And Therapeutics – AACR Report
As genomic analysis produces ever-increasing amounts of data on cancer biology, continued progress in oncology will require advances in managing and analyzing data and new approaches to clinical trial design to increase efficiency and address development of treatment resistance to molecularly targeted therapies, the American Association for Cancer Research asserts in its annual Cancer Progress report.
Cancer Progress Requires Integrating Data And Therapeutics – AACR Report
As genomic analysis produces ever-increasing amounts of data on cancer biology, continued progress in oncology will require advances in managing and analyzing data and new approaches to clinical trial design to increase efficiency and address development of treatment resistance to molecularly targeted therapies, the American Association for Cancer Research asserts in its annual Cancer Progress report.